Artificial Inc., of Palo Alto, Calif., reported a strategic technology collaboration to develop an integrated and comprehensive software automation platform for Waltham, Mass.-based Thermo Fisher Scientific Inc.’s standardized COVID-19 testing platform.

Jerusalem-based Brainsway Ltd. has inked an exclusive distribution agreement with Gaelan Medical Trade LLC, a member of the Dubai-based Ghassan Aboud Group, establishing a multiyear framework whereby Brainsway will supply its Deep Transcranial Magnetic Stimulation system for the treatment of brain disorders, including major depressive disorder, throughout the United Arab Emirates.

Miami-based digital health provider Emed said it will begin administering the FDA-authorized, at-home, symptomatic Binaxnow COVID-19 Ag Card rapid home test to 100,000 qualified individuals across the U.S. who order through Emed beginning today. The Binaxnow test is made by Abbott Laboratories, of Abbott Park, Ill.

Flurotech Ltd., of Calgary, Alberta, said that Flurotest Ltd. has retained San Diego-based Nanocomposix Inc. to immediately begin lab performance studies for Flurotest’s rapid antigen testing pandemic defense platform. The move brings Flurotest one step closer to submitting to the U.S. FDA for emergency use authorization.

Renalsense Ltd., a Jerusalem, Israel-based developer of a continuous, automatic monitor for early detection of acute kidney injury, reported a distribution agreement with Medtechnica Ltd., of Petah Tikva, Israel. Medtechnica will market Renalsense’s Clarity Rms critical care monitoring system to hospitals throughout Israel.

Roche Group, of Basel, Switzerland, signed a global business partnership (GBP) agreement with Sysmex Corp., of Kobe, Japan. Roche renewed its commitment to continue to distribute Sysmex hematology products, including instruments and reagents, and entered a new information technology (IT) solutions collaboration agreement. The companies have agreed to use their respective IT platforms to improve customer experience, in the short to mid-term, with a long-term goal of using the IT systems to lead to improved clinical decision making. The GBP agreement will run until the end of 2030.

Therapeutic Solutions International Inc., of Oceanside, Calif., reported preclinical findings on Stemvacs, an umbilical cord generated dendritic cell immunotherapy. Stemvacs administration was demonstrated to induce regression of GL261 glioma, CT-26 colorectal cancer and Lewis lung carcinoma tumors grown in mice.

Volitionrx Ltd., the Austin, Texas-based developer of Nu.Q, reported the opening of Silver One, its 10,000 square foot dedicated manufacturing facility located in the same science park as its R&D laboratory in Isnes, Belgium.